Accessibility Menu
Phio Pharmaceuticals logo

Phio Pharmaceuticals(NASDAQ) PHIO

Market Cap$12.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-100%
5 Year-99%
1 Year-62%
1 Month+8%
$1.05
+0.96%
+0.01Today
Phio Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.052026-07-27
Phio Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.78%USD 1.082026-07-20
1 month+8.25%USD 0.972026-06-26
3 month-12.5%USD 1.202026-04-28
Year to date+0%USD 1.052025-12-31
1 year-61.68%USD 2.742025-07-25
3 year-95.79%USD 24.932023-07-28
5 year-99.47%USD 198.722021-07-28
Since inception-100%USD 2,317,290.552012-05-10

Phio Pharmaceuticals Financials at a Glance

Market Cap

$12.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.93M

EPS (TTM)

-$1.44

P/E Ratio

-0.72

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$1.05

Volume

2,824

Open

$1.06

Previous Close

$1.05

Daily Range

$1.04 - $1.06

52-Week Range

$0.81 - $4.19

Estimated Earnings Date

Aug 13, 2026

PHIO News

Foolcom-Featured.png

Phio Posts Wider Loss in Fiscal Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Phio Pharmaceuticals

Phio develops medicines that help the immune system fight cancer. Its main products aim to make immune cells better at finding and destroying tumors. These treatments are designed for people with hard-to-treat cancers.

Lab Bench to Bedside: What Phio Sells

  • INTASYL Platform: Technology that delivers gene-silencing molecules directly into immune and tumor cells. (0% of revenue; no product sales)
  • PH-762: Drug candidate that helps immune cells attack cancer by blocking a protein called PD-1. (0% of revenue)
  • PH-894: Experimental treatment that turns off a gene regulator, BRD4, to boost immune cell activity. (0% of revenue)
  • PH-804: Early-stage therapy targeting TIGIT, a protein that slows immune cells, for use in cell-based cancer treatments. (0% of revenue)

Growth Spurts and Growing Pains

  • Changed name from RXi Pharmaceuticals to Phio in 2018.
  • Launched Phase 1b trial for PH-762 in 2024.
  • Ended collaboration with AgonOx in May 2024, reducing future obligations.
  • Raised $6.7 million in equity and warrants in late 2024 and early 2025.
  • Cut workforce by over 50% in early 2024 and moved to remote operations in April 2024.

Why Phio Is a Bit Different

Phio’s technology lets gene-silencing drugs enter cells without extra delivery tools. This approach targets proteins inside cells that are hard to reach with standard drugs. The company’s treatments can be added to cell-based cancer therapies, aiming to improve their effectiveness.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Operating loss was $2.3 million in Q2 2025, up 20.6% from Q2 2024.
  • Cash and equivalents were $10.8 million as of June 30, 2025, up from $5.4 million at December 31, 2024.
  • Net cash used in operations was $3.8 million for the first half of 2025.
  • Company had 5 full-time employees as of June 2025.

Bottom Line

Phio remains focused on early-stage cancer drug development with no product sales to date. The company relies on new funding and faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Robert J. Bitterman, Sr., MBA

Website

www.phiopharma.com

Headquarters

Marlborough, MA 19406, US

PHIO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-77.34%

Return on Capital

-45.76%

Return on Assets

-62.78%

Earnings Yield

-1.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.62M

Volume

2.82K

Avg. Volume

616.01K

Financials (TTM)

Gross Profit

-$3.73M

Operating Income

-$11.52M

EBITDA

-$10.93M

Operating Cash Flow

-$10.71M

Capital Expenditure

-$10.00K

Free Cash Flow

-$10.72M

Cash & ST Invst.

$17.03M

Total Debt

$0.00

Phio Pharmaceuticals Performance Analysis

Phio Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Phio Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Phio Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -90.90-18.7%
20232023-12-31USD -46.76-48.6%
20242024-12-31USD -9.08-80.6%
20252025-12-31USD -1.45-84.0%
Phio Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30100.0%
Q32025-09-302.2%
Q42025-12-3154.5%
Q12026-03-31-70.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.00K

+93.3%

Gross Margin

0.00%

N/A

Market Cap

$12.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.01M

N/A

Employees

6

N/A

Net Income

-$4.00M

-126.3%

EBITDA

-$4.00M

-126.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$17.03M

+28.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-62.78%

N/A

Return on Invested Capital

-67.14%

N/A

Free Cash Flow

-$4.00M

-213.5%

Operating Cash Flow

-$4.00M

-214.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INABIN8bio, Inc.
$1.19-0.83%
KPRXKiora Pharmaceuticals, Inc.
$2.54-0.39%
MRKRMarker Therapeutics, Inc.
$1.22+0.00%
APVOAptevo Therapeutics Inc.
$4.21-4.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About PHIO

What is the current price of Phio Pharmaceuticals?

Phio Pharmaceuticals is trading at $1.05 per share.

What is the 52-week range for Phio Pharmaceuticals?

Over the past 52 weeks, Phio Pharmaceuticals has traded between $0.81 and $4.19.

How much debt does Phio Pharmaceuticals have?

As of the most recent reporting period, Phio Pharmaceuticals reported total debt of $0.00.

How much cash does Phio Pharmaceuticals have on hand?

Phio Pharmaceuticals reported $17.03M in cash and cash equivalents in its most recent financial results.

What is Phio Pharmaceuticals’s dividend yield?

Phio Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services